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ess: p.wark@soton.ac.uSummary Background: Allergic bronchopulmonary aspergillosis (ABPA) is a com-
plex condition that affects people with asthma and cystic fibrosis (CF). It results
from exposure to the fungus Aspergillus fumigatus, which leads to worsening airway
inflammation and progressive damage to the lungs. The aim of this review is to
outline the pathogenesis of the disorder, diagnostic criteria and to discuss the use of
anti-fungal agents in its treatment.
Methods: The Cochrane library of systematic reviews and the Cochrane database
of controlled trials were searched for controlled trials on ABPA and its treatment in
both asthma and CF. In addition, articles included within the reviews were examined
separately, and a separate search carried out using Medline.
Results: A systematic review for the use of azole anti-fungal agents in ABPA was
identified for their use in both CF and non-CF-related disease. The review of ABPA
alone identified two randomized-controlled trials of itraconazole in chronic disease.
These trials demonstrated improvements in symptoms and immune activation, but
were short-term trials and failed to show a significant change in lung function. No
trials were identified in CF.
Conclusions: The use of anti-fungal agents in ABPA seems to be a rational one,
with short-term efficacy demonstrated for the use of itraconazole. Further
investigations are required to identify individuals who will benefit most from
treatment and to establish the correct dose and means of delivering treatment in
ABPA. Longer-term studies are required to demonstrate that treatment modifies the
progressive decline in lung function seen with the disease.
r 2004 Elsevier Ltd. All rights reserved.4 Elsevier Ltd. All rights reserved.
s been cited in this evidence-based review: Wark PAB, Gibson PG, Wilson AJ. Azoles for allergic
ted with asthma. The Cochrane Library, Issue 4, 2003. Copyright Cochrane Library, reproduced
k (P. Wark).
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Aspergillus fumigatus (Af) is a spore-forming
saprophytic fungus that is ubiquitous to the
environment. It is responsible for a range of
pulmonary diseases. These include severe life-
threatening pneumonia in immunosuppressed peo-
ple, subacute infections, such as the formation of
aspergilloma in pulmonary cavities (a form of
extrinsic allergic alveolitis) and hypersensitivity
diseases.1 People with asthma or cystic fibrosis (CF)
may become sensitized to Af after inhalation of
spores. Once sensitized, this results in a type I, IgE-
mediated reaction and a spectrum of clinical
responses. These range from acute exacerbations
of asthma to a more sustained and intense
inflammatory response (demonstrating features of
both type I and type III hypersensitivity), and leads
to allergic bronchopulmonary aspergillosis (ABPA).2
ABPA is a complex condition that was first
described in the UK in 1952.3 It has been estimated
to occur in 1–2% of chronic asthmatics4 and 2–15%
of people with CF.5 This review will focus on the
pathogenesis of ABPA, with particular emphasis on
the potential pathogenic role of Af and the
rationale for the use of antifungal treatment.
Secondly, I will review the evidence for the use of
azole antifungal agents in the treatment of ABPA.Immunopathogenesis of ABPA
Af is an effective pathogen in humans because
intrinsic qualities of the organism have evolved,
which enhance its ability to infect the lungs and
cause disease. The spores of Af are 2–5 mm in size,
with a hydrophobic coat that allows them to be
inspired into the lungs.6 Once respired, the conidia
of Af are able to bind to surfactant molecules in the
distal airway lumen,7 as well as complement (C3)8
and fibrinogen.9 The conidia germinate within the
airways and form hyphae; the mature organisms are
capable of releasing allergens, virulence factors
and proteases.10–13 These factors contribute to (1)
impaired mucociliary clearance; (2) impaired ac-
tion of fungicidal proteins and complement in the
airway lining fluid; (3) inhibition of phagocytosis
and the killing capacity of phagocytic cells (macro-
phages and neutrophils). It is of particular rele-
vance to asthma and the treatment of ABPA that
neutrophil killing of Af is suppressed by corticos-
teroids.14
As the organism is ubiquitous in the environment,
sensitized individuals are likely to inhale spores
regularly, and this will always represent a freshsource of antigenic stimulus. However, Af is unique,
as an aeroallergen, and inhalation alone is insuffi-
cient to lead to ABPA. Persistence of viable Af
within the airways seems to be an important factor
in determining the development of ABPA. Viable Af
has been found growing on and between bronchial
epithelial cells, despite an intense inflammatory
cell infiltrate,15 whereas Af proteases lead to the
release of pro-inflammatory mediators from
epithelial cells.13,16 These proteases also have the
ability to detach epithelial cells from their base-
ment membrane,13 inevitably leading to a loss of
epithelial integrity. Although other proteases, such
as those derived from house dust mite allergen
have been found to similarly detach epithelial
cells,17 the proteases released by Af are particu-
larly potent, even with few organisms present.18
This loss of epithelial integrity may lead to
exposure of the underlying matrix, to which Af
can also adhere,19 with important implications to
direct damage of the airways and the development
of bronchiectasis. This intense recruitment of
inflammatory cells to the airway lumen, and the
development of progressive airway wall damage, is
in keeping with airway inflammation found in
patients with ABPA and the development of
bronchiectasis.20
In addition to the direct effect Af has on the
airway epithelium, it seems to be able to elicit a
powerful TH2-immune response. The presence of
Af infection in mice induces a Th2-lymphocyte
response.21,22 The extracts from Af, when co-
cultured with B cells, elicit the release of IgE,23
and people with ABPA develop a specific Th2 CD4+
in response to exposure.24
Clearly, only a minority of people with asthma or
CF develop ABPA. A genetic predisposition is
suggested by reports of a familial occurrence of
ABPA.25,26 In the case of CF, the presence of atopy
seems to be important, suggesting that an allergic-
type response to the pathogen impairs the ability to
clear it, whereas the pre-existing airway inflamma-
tion and impaired mucociliary clearance may
provide a favourable environment for Af to exist.
In the case of patients with asthma and ABPA, two
small studies have shown a higher carriage rate of
at least one mutation of the CF transmembrane
regulator (CFTR) gene in people with ABPA,
compared with people with positive skin tests to
Af and with asthma alone.27,28 The alleles HLA-DR2
and DR5 have been linked to severity of disease in
ABPA.24,29 Most recently, a polymorphism of surfac-
tant proteins has been shown to be associated with
increased serum IgE and blood eosinophilia in
patients with ABPA.30 These findings suggest there
may be a link between ABPA and an inability to
ARTICLE IN PRESS
Pathogenesis of ABPA 917clear the organism effectively in a group whose
immune response is likely to be one of hypersensi-
tivity.
In summary, we have seen the development of a
model for the pathogenesis of ABPA in recent years,
in which the susceptible individual acquires Af in
their lungs where it is able to germinate and
persist. Consequently, it attaches to the epithelial
cells, resulting in release of pro-inflammatory
mediators and an influx of granulocytes. Viable Af
releases proteases, which damage the epithelial
layer. These exacerbate inflammation and expose
the immune system to Af-associated allergens,
which elicit an intense Th2-type immune response.
A combination of these components is likely to
account for the development of progressive fibrosis
and bronchiectasis. Although traditional treatment
has focused on suppressing the immune reaction to
these phenomena, with high-dose corticosteroids,
the presence of viable organisms driving this
process makes the option of antifungal chemother-
apy an attractive adjunct.Diagnosis and clinical course of the
disease
The criteria for diagnosis were standardized in 1977
by Patterson et al.31,32 They require the patient to
fulfil the following criteria: (1) a pre-existing
diagnosis of asthma (or CF); (2) immediate-type
skin reactivity to Af; and (3) peripheral blood
eosinophilia, precipitating antibodies to Af antigen,
elevated serum IgE, elevated serum IgE and IgG
antibodies against Af (at least during exacerbations
or in the absence of treatment). Radiological
evidence of proximal bronchiectasis is a frequent
accompaniment of ABPA, but is not now felt to be a
prerequisite for diagnosis.32,33 However, the pre-
sence of bronchiectasis along with skin-test reac-
tivity and eosinophilia is quite specific for ABPA.
The disease has been subdivided into five
stages.31 Stage one is the initial acute presenta-
tion, with eosinophilia, immediate-type skin reac-
tivity to Af, total serum IgE greater than 2500 ng/
ml and pulmonary infiltrates on a chest radiograph.
Stage two is the disease in remission, where there
is persistent immediate-type skin reactivity and
precipitating antibodies to Af antigens. In stage
three, symptoms exacerbate, with all the char-
acteristics of stage one, a two-fold rise in serum IgE
and new pulmonary infiltrates. Stage four patients
have asthma, and control of symptoms is depen-
dent on chronic use of high-dose corticosteroids. In
stage five, chronic disease has progressed topredominately fixed airflow obstruction, with ex-
tensive bronchiectasis and fibrosis.
There may be a wide spectrum of disease activity
in ABPA, and diagnosis is made more easily in those
with severe disease; however, diagnosis and treat-
ment of people with mild disease may prevent
progressive disease. In milder disease, a high index
of suspicion is required, with the criteria fulfilled
only during an exacerbation or when off parenteral
corticosteroids.
Skin-prick testing is a useful screening test to
identify people wth potential ABPA. It is highly
sensitive but not specific. Consequently, a negative
skin-prick test to Af can rule out ABPA, whereas a
positive test warrants further investigation, parti-
cularly in the case of asthmatic people with
frequent exacerbations or corticosteroid depen-
dence. Patients with a positive skin test should be
evaluated with serology, including measurement of
total serum IgE, specific IgG and IgE antibodies to
Af and precipitins. The presence of peripheral
blood eosinophilia and cultures of Af from sputum is
not mandatory but is corroborative. Patients with
an IgE of over 1000 ng/ml (400 IU/ml) and positive
IgE Af and IgG Af are likely to have ABPA, and
warrant further investigation with a high resolution
computed tomography of the chest to determine
the presence of bronchiectasis. Patients with
central bronchiectasis then are classed as ABPA-
CB (ABPA with central bronchiectasis), those with-
out, ABPA-S (ABPA serology).34 Those who do not
have immunological evidence of ABPA when tested
will need to be reviewed.
Practice points
Diagnosis in classic ABPA
 Immediate skin-prick test positive to Af.
 Total serum IgE greater than 1000 ng/ml
(400 IU/ml).
 Serum-specific IgG and IgE antibodies to Af
(or positive precipitins).
 Presence of bronchiectasis
J Yes, ABPA-CB.
J No, ABPA-S.Diagnosis in CF is more difficult, and is compli-
cated by the presence of a disorder that indepen-
dently leads to bronchiectasis and fibrosis. These
criteria have recently been reviewed and standar-
dized by a consensus conference.5 The consensus
statement suggests the diagnosis be made in the
presence of (1) an acute or subacute deterioration
in clinical symptoms (cough, wheeze, exercise
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in sputum) not attributable to another cause; (2) a
total serum IgE greater than 400 IU/ml; and (3)
immediate skin-test reactivity to Af along with one
of the following: precipitins to Af or specific IgG to
Af, new or recent infiltrates, mucus plugging or
proximal bronchiectasis on either chest radiograph
or computed tomography. A multiple-regression
analysis of over 14,000 individuals with CF deter-
mined that wheezing, a diagnosis of bronchial
asthma and colonization with P. Aeruginosa, were
independent risk factors for ABPA.35 As is the case
with asthma, the development of ABPA in someone
with CF heralds a more complicated clinical course
and is associated with more bacterial colonization,
lower lung function and an increase in pulmonary
complications.36,37
Practice points
Diagnosis in CF
 Acute or subacute deterioration in respira-
tory symptoms or lung function.
 Total serum IgE greater than 400 IU/ml.
 Skin-prick test positive to Af, together with
either
o Positive Aspergillus precipitins
o Radiographic features consistent with
ABPA.Management of ABPA with azole
antifungal agents
Up until recently, corticosteroids have been the
cornerstone for management of ABPA, and a more
detailed review of their use is provided else-
where.38 Prednisolone is highly effective in treating
acute exacerbations of disease,31 but patients
require relatively high doses to suppress acute
exacerbations, and it is unclear how much they
prevent the progression of lung disease.39 The
considerable side-effects of long-term corticoster-
oids make alternative therapies worthwhile inves-
tigating.
The currently available antifungal agents with
known efficacy against Af are amphotericin B and
the azoles (ketoconazole, itraconazole and vorico-
nazole). Treatment of Aspergillus infection with
amphotericin is effective, and has even been used
as a nebulized preparation for chemoprophylaxis in
at-risk immunosuppressed people. However, its use
has been limited by its toxicity and cost.40 Azolesare effective, easy to administer and have favour-
able side-effect and cost profiles. They inhibit
ergosterol synthesis in the fungal cell membrane,
and thereby inhibit fungal growth.Ketoconazole
Shale et al.41 studied 10 patients with mild, stable
ABPA who were on maintenance-inhaled corticos-
teroids, and reported that ketoconazole signifi-
cantly reduced specific IgG antibody to Af, total IgE
and Af-specific IgE after 12 months (Po0:05). There
was also a significant improvement in symptom
scores, which correlated with the change in the IgG
levels, but no significant changes in lung function.
In contrast to these findings, Fournier et al.42
previously failed to show a benefit from ketocona-
zole 400mg daily in nine uncontrolled cases, all of
which were also on 10–15mg of prednisone daily.
Long-term ketoconazole use would, however, be
complicated by its side-effects. It is a rare cause of
severe hepatic disease (1 in 10,000) and, in a dose-
dependent manner, it is associated with sexual
dysfunction inhibition of testosterone and adreno-
cortical function.43Itraconazole in ABPA
Itraconazole has fewer side-effects and a wider
spectrum of activity than ketoconazole. The main
side-effects are dose-related nausea and vomit-
ing.43 Itraconazole is effective for invasive asper-
gillosis, and the outcome for pulmonary disease is
better than for other sites.44 Several retrospective
trials or case series have looked at the use of
itraconazole in ABPA or have included patients with
ABPA and other forms of aspergillus-related pul-
monary disease (Table 1). All but two of these
studies45,46 have been uncontrolled, and most have
had small numbers. Despite this, they have
consistently shown positive results.
A systematic review assessing the evidence for
the use of azoles in ABPA without CF has been
carried out.47 The review identified only two
randomized-controlled trials.45,46 The RCT by
Stevens et al.45 was a parallel, randomized,
double-blind, placebo-controlled trial of itracona-
zole 200mg twice daily for 16 weeks. Inclusion
criteria were an FEV1/FVC ratio of less than 0.7,
immediate skin test positive to Aspergillus, an
elevated total serum IgE, IgG antibodies to Asper-
gillus, a history of pulmonary infiltrates and
dependence on oral corticosteroids. Participants
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Table 1 The use of itraconazole in the treatment of ABPA.
Study Study format Intervention (sample size) Results*
Stevens et al.45 Randomized, double-
blind trial
Itraconazole 200mg four times daily for 16 weeks;
200mg twice daily for 16 weeks (open for 16
weeks (n ¼ 55)
IPS
Wark et al.46 Randomized double blind
trial
Itraconazole 400mg daily for 16 weeks (n ¼ 32) IPS
Neopmuceno et al.49 y Retrospective case
control study
Itraconazole? Dose (n ¼ 16) S
LeBeau et al.52 Case series Itraconazole 200-400mg/day (n ¼ 3) S
Mannes et al.50 y Case series (letter) Itraconazole 200mg BD (n ¼ 2) IP
Germaud et al.53 Case series (abstract) Itraconazole 200mg/day for 6 months (n ¼ 12) IS
Denning et al.48 y Case series Itraconazole 200mg BD (n ¼ 6) IS
De Beule et al.54 Case series 50–400mg/d for 43–239 days (n ¼ 5) S
Nikaido et al.55 Case report Itraconazole 100mg/day (n ¼ 1) I
Matsuzaki et al.56 Case report Itraconazole 200mg/day for 1 month (n ¼ 1) S
Pacheco et al.57 Case report (letter) Itraconazole 200mg/day for 4 month (n ¼ 1) IP
*Results: I=improvement (Po0:05) in Af serology and immunology tests; P=improvement (Po0:05) in pulmonary function
tests; S=improvement (Po0:05) in symptoms.
yIncludes people with cystic fibrosis.
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recruited. The study recruited 55 participants from
13 centres on at least 10mg of prednisone daily,
and randomized them to itraconazole or placebo.
The itraconazole arm received 200mg twice daily
initially for 16 weeks. Steroid reduction was
attempted. The study was then unblinded, and all
received 200mg daily for a further 16 weeks. In the
treatment group, 46% of participants achieved an
improvement in one of the following outcome
parameters: a 50% or more reduction in oral
corticosteroid dose, a 25% or greater fall in IgE,
or a 25% increase in pulmonary function tests
(FEV1, FVC, diffusion of carbon dioxide across the
lung [DLCO], FEF and peak flow) or exercise
tolerance. Only 19% of the placebo group met one
of these criteria for improvement (Fisher’s exact
test: P ¼ 0:04). Although the difference between
the groups was significant in terms of overall
response, it failed to reach statistical significance
for each of these outcomes when examined
separately. Adverse events were similar in both
groups. Quality-of-life scores were not significantly
different.
Wark et al.46 conducted a parallel-group, rando-
mized, double-blind, placebo-controlled trial of
itraconazole 400mg daily for 16 weeks with 29
participants. Inclusion criteria were as follows:
asthma with evidence of variable airflow obstruc-
tion, immediate skin sensitivity to Af, positive
serum IgE and IgG antibodies to Af, a serum totalIgE of over 1000 ng/ml. The primary outcomes were
markers of airway inflammation measured using
induced sputum. Participants who received itraco-
nazole had a 35% reduction (95% CI 20–48%
reduction) in sputum eosinophils, which was sus-
tained throughout the trial, whereas the placebo
arm showed no change (the 95% CI included a 19%
fall and a 12% increase). There was a similar fall in
sputum eosinophil cationic protein, a marker of
eosinophil degranulation and airway inflammation.
The itraconazole group showed a 42% fall (95% CI
19, 58% reduction), the placebo group had a 23%
fall (the 95% CI included a 66% fall and a 30%
increase). There was a similar fall in systemic
immune activation. Participants taking itracona-
zole had a median fall in serum IgE of 310 IU/ml
compared with a rise in the placebo group of 18 IU/
ml (Po0:001). These data from the two trials were
pooled and analysed.47 The proportion of partici-
pants with a decline in serum IgE of at least 25% was
significantly greater with itraconazole than with
placebo (odds ratio 3.26 [1.30 to 8.15]) (Fig. 1).47
Wark et al.46 also showed that participants taking
itraconazole had less exacerbations of their chest
disease requiring the use of oral corticosteroids
during the period of the trial, with a mean number
of exacerbations per participants of 0.4 (standard
deviation [SD] 0.5) compared with placebo 1.3 (SD
1.2); P ¼ 0:03: They did not demonstrate any
statistically significant change in lung function,
although the itraconazole arm recorded an increase
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Figure 1 Fall in total serum IgE by 25% or more after treatment with itraconazole. Reproduced with permission from
the Cochrane Library.
P. Wark920in FEV1 of 7.9% and the placebo arm a fall of 1.9%
(P ¼ 0:5). The proportion who had an increase in
FEV1 of 25% or more was pooled with data from
Stevens et al.45 for participants who had an
improvement in lung-function parameters.47 Parti-
cipants taking itraconazole did not show an
improvement in lung function (OR 2.15
[0.85–5.46]) (Fig. 2).
One participant withdrew from the trial by Wark
et al.46 because of nausea related to itraconazole
use, but there were no other serious adverse
events.
The evidence from these two trials demonstrates
that itraconazole reduces the inflammation asso-
ciated with ABPA and improves clinical outcomes
over 16 weeks. As both the intensity of the
inflammatory response and acute exacerbations of
the disease are felt to lead to progressive lung
disease, the ability of itraconazole to modify both
of these factors in the short term may have
important implications for the chronic management
of the disease.Itraconazole in treatment of ABPA in
patients with cystic fibrosis
Neither randomized trials of itraconazole included
participants with CF. Three case series have been
published,48–50 which have included participants
with CF (n ¼ 18). All demonstrated small improve-
ments in lung function, symptoms or a reduction in
corticosteroid usage (Table 1). Skov et al.51reported a patient with CF who developed Cush-
ing’s syndrome while using inhaled corticosteroids
and itraconazole. They then went on to show that,
in participants with CF, co-existent use of inhaled
budesonide and itraconazole led to suppression of
adrenal glucocorticoid synthesis in 11 out of 25
participants. This is potentially an important
adverse event, and its occurrence should be
considered when planning future trials in all people
with ABPA.
Practice point
Treatment with itraconazole
 Itraconazole therapy reduces immune acti-
vation in ABPA.
 Itraconazole improves short-term symptoms
and reduces the frequency of exacerbations
that require the use of oral corticosteroids.
 Short-term use of itraconazole has not
shown an improvement in lung function.
 Itraconazole may exacerbate the adrenal
suppression seen with regular corticosteroid
use.Voriconazole
Voriconazole is the newest of the azole anti-
fungal agents, and has been effective in the
treatment of invasive pulmonary aspergillosis in
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Figure 2 Improvement in lung function tests by 25% or more after treatment with itraconazole. Reproduced with
permission of the Cochrane Library.
Pathogenesis of ABPA 921immunosuppressed people. So far, its use has not
been reported in the treatment of ABPA.Conclusions and future directions
Allergic bronchopulmonary aspergillosis remains an
important complication of both asthma and cystic
fibrosis. It contributes to worsened morbidity and
progressive deterioration in lung function. Af is
well adapted to survive in the human airway, and
persistence of the organism is a constant source of
antigenic stimulus. Evidence shows that it can
release virulence factors and proteases, contribut-
ing to a more heterogenous inflammatory response
that is likely to play a central role in the
development of bronchiectasis and progressive lung
damage.
The drive to find novel therapeutic interventions
in ABPA is with the aim of preventing progressive
decline in lung function and consequent worsening
respiratory impairment, while minimising the use
of systemic corticosteroids. The use of antifungal
therapy, therefore, seems to be a rational one in
association with more traditional anti-inflamma-
tory therapy. Both the randomized-controlled trials
of itraconazole45,46 demonstrated improvements in
symptoms and immune activation, but were short-
term trials and failed to show a significant change
in lung function.
Important questions remain unanswered. Lower
doses of itraconazole may be effective, particularlyfor maintaining disease. Alternatively, administra-
tion by nebulization should be explored, given the
previous success with amphotericin. This could be
used in a similar way to nebulized antibiotics in CF,
with the potential of delivering an effective dose to
the lungs but minimising systemic side-effects. It
also remains unclear which patients will benefit
most from treatment. Individuals with a high
pathogen burden may stand to benefit most;
however, at this time there is no reliable way to
determine this. Mechanistic studies relating endo-
bronchial biopsy findings that attempt to quantify
Af from bronchoalveolar lavage or its presence in
the sputum, and correlating this to airway inflam-
mation and clinical disease, would help answer
this. Susceptibility of Af to treatment with itraco-
nazole may also affect efficacy as was identified by
Stevens et al.45 It would be prudent that future
trials assess in-vitro sensitivity in individuals at the
start and during long-term treatment trials, and
determine if this relates to efficacy. The current
studies show that serum IgE or sputum inflamma-
tory markers can be used to assess response in
short-term efficacy studies, and many of these
issues could be determined, therefore, by smaller
single-centre studies. However, the most important
outstanding questions remain whether treatment
will modify disease progression and for how long
that treatment should be. As most patients with
ABPA have long-standing lung disease, with a
component of irreversible airflow obstruction,
larger numbers of participants with longer follow-
up will be required to detect a difference, such as
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ment over time. In addition, adverse events such as
adrenal suppression may only be evident over time
and with associated use of corticosteroids. Realis-
tically, to achieve an estimate of these events, trial
periods of 2–5 years may be required. As the
minimum number of particpants required would
need to be similar to the number recruited by
Stevens et al.,45 this could only be achieved by a
multicentre collaborative trial.
These results cannot be automatically extrapo-
lated to CF, and there is a need to assess the
efficacy of itraconazole specifically in ABPA asso-
ciated with CF, particularly in the context of the
regular use of antibiotics and agents to increase
mucociliary clearance. In addition, diagnosis in CF
remains problematic, and a clearer understanding
of the pathogenesis of ABPA in CF is required along
with the ability to detect the disease more reliably
and at an early stage.
Therefore, antifungal therapy with itraconazole
seems, at least in the short term, to modify the
immune activation seen with ABPA and improve
symptoms. Longer-term trials are likely to be needed
to demonstrate an improvement in lung function.
Questions also remain as to what the correct dose
should be, when itraconazole should be commenced
and for what period of time? A consideration of these
issues needs to be made before the widespread
regular use of itraconazole is adopted.
Research directions
 Longer-term trials are required to assess the
impact of itraconazole on lung function and
disease course in ABPA.
 Smaller short-term trials are needed to
determine the dosing schedule and the most
effective means of delivering treatment.
 In-vitro sensitivity testing of Af to antifungal
treatment should be considered in future
trials.
 The additive effect of itraconazole on
adrenal suppression associated with corti-
costeroid use needs to be closely observed
with long-term use and its effect on bone-
mineral density considered in all future
trials of long-term therapy.
 The role of antifungal agents in acute
exacerbations of the disease needs to be
determined.
 The role of antifungal agents to treat ABPA
in CF needs to be addressed in separate
clinical trials both in terms of efficacy and
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